Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 9/2020

01-09-2020 | Translational Research and Biomarkers

ANO9 Regulated Cell Cycle in Human Esophageal Squamous Cell Carcinoma

Authors: Keita Katsurahara, MD, Atsushi Shiozaki, MD, PhD, Toshiyuki Kosuga, MD, PhD, Michihiro Kudou, MD, PhD, Katsutoshi Shoda, MD, PhD, Tomohiro Arita, MD, PhD, Hirotaka Konishi, MD, PhD, Shuhei Komatsu, MD, PhD, Takeshi Kubota, MD, PhD, Hitoshi Fujiwara, MD, PhD, Kazuma Okamoto, MD, PhD, Mitsuo Kishimoto, MD, PhD, Eiichi Konishi, Yoshinori Marunaka, MD, PhD, Eigo Otsuji, MD, PhD

Published in: Annals of Surgical Oncology | Issue 9/2020

Login to get access

Abstract

Background

Few studies have reported the function and activation mechanism of ANO9 in esophageal squamous cell carcinoma (ESCC). The current study aimed to investigate the role of ANO9 in the regulation of tumor progression.

Methods

Knockdown experiments with human ESCC cell lines were performed using ANO9 siRNA, and the effects on cell proliferation, the cell cycle, apoptosis, and cellular movement were analyzed. Immunohistochemistry (IHC) analysis was performed on 57 primary tumor samples obtained from ESCC patients.

Results

In an in vitro study, depletion of ANO9 reduced cell proliferation, invasion, and migration in KYSE150 and KYSE 790 cells. In the cell cycle analysis, depletion of ANO9 increased the number of cells in G0/G1 arrest. In addition, the knockdown of ANO9 increased apoptosis. The results of the microarray analysis indicated that various centrosome-related genes such as CEP120, CNTRL, and SPAST were up- or downregulated in ANO9-depleted KYSE150 cells. The IHC results showed that high expression of ANO9 was associated with poor prognosis.

Conclusions

The results of the current study suggest that ANO9 regulates the cell cycle via centrosome-related genes in ESCC.
Appendix
Available only for authorised users
Literature
1.
Schreiber R, Uliyakina I, Kongsuphol P, et al. Expression and function of epithelial anoctamins. J Biol Chem. 2010;285:7838–45.PubMedPubMedCentral
2.
Brunner JD, Schenck S, Dutzler R. Structural basis for phospholipid scrambling in the TMEM16 family. Curr Opin Struct Biol. 2016;39:61–70.PubMed
3.
Kunzelmann K. TMEM16, LRRC8A, bestrophin: chloride channels controlled by Ca(2+) and cell volume. Trends Biochem Sci. 2015;40:535–43.PubMed
4.
Wanitchakool P, Wolf L, Koehl GE, et al. Role of anoctamins in cancer and apoptosis. Philos Trans R Soc Lond B Biol Sci. 2014;369:20130096.PubMedPubMedCentral
5.
Pedemonte N, Galietta LJ. Structure and function of TMEM16 proteins (anoctamins). Physiol Rev. 2014;94:419–59.PubMed
6.
Kunzelmann K, Tian Y, Martins JR, et al. Anoctamins. Pflugers Arch. 2011;462:195–208.PubMed
7.
Kunzelmann K, Kongsuphol P, Chootip K, et al. Role of the Ca2+-activated Cl– channels bestrophin and anoctamin in epithelial cells. Biol Chem. 2011;392:125–34.PubMed
8.
Kunzelmann K, Kongsuphol P, Aldehni F, et al. Bestrophin and TMEM16-Ca(2+) activated Cl(−) channels with different functions. Cell Calcium. 2009;46:233–41.PubMed
9.
Duran C, Hartzell HC. Physiological roles and diseases of Tmem16/Anoctamin proteins: are they all chloride channels? Acta Pharmacol Sin. 2011;32:685–92.PubMedPubMedCentral
10.
Hartzell HC, Yu K, Xiao Q, Chien LT, Qu Z. Anoctamin/TMEM16 family members are Ca2+-activated Cl− channels. J Physiol. 2009;587(Pt 10):2127–39.PubMed
11.
Lu G, Shi W, Zheng H. Inhibition of STAT6/anoctamin-1 activation suppresses proliferation and invasion of gastric cancer cells. Cancer Biother Radiopharm. 2018;33:3–7.PubMed
12.
Wu H, Wang H, Guan S, et al. Cell-specific regulation of proliferation by ANO1/TMEM16A in breast cancer with different ER, PR, and HER2 status. Oncotarget. 2017;8:84996–5013.PubMedPubMedCentral
13.
Seo Y, Ryu K, Park J, et al. Inhibition of ANO1 by luteolin and its cytotoxicity in human prostate cancer PC-3 cells. PLoS ONE. 2017;12:e0174935.PubMedPubMedCentral
14.
Fujimoto M, Inoue T, Kito H, et al. Transcriptional repression of HER2 by ANO1 Cl(−) channel inhibition in human breast cancer cells with resistance to trastuzumab. Biochem Biophys Res Commun. 2017;482:188–94.PubMed
15.
Shang L, Hao JJ, Zhao XK, et al. ANO1 protein as a potential biomarker for esophageal cancer prognosis and precancerous lesion development prediction. Oncotarget. 2016;7:24374–82.PubMedPubMedCentral
16.
Jia L, Liu W, Guan L, Lu M, Wang K. Inhibition of calcium-activated chloride channel ANO1/TMEM16A suppresses tumor growth and invasion in human lung cancer. PLoS ONE. 2015;10:e0136584.PubMedPubMedCentral
17.
Bill A, Gutierrez A, Kulkarni S, et al. ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer. Oncotarget. 2015;6:9173–88.PubMedPubMedCentral
18.
Britschgi A, Bill A, Brinkhaus H, et al. Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling. Proc Natl Acad Sci USA. 2013;110:E1026–34.PubMedPubMedCentral
19.
Suzuki J, Fujii T, Imao T, Ishihara K, Kuba H, Nagata S. Calcium-dependent phospholipid scramblase activity of TMEM16 protein family members. J Biol Chem. 2013;288:13305–16.PubMedPubMedCentral
20.
Dutertre M, Lacroix-Triki M, Driouch K, et al. Exon-based clustering of murine breast tumor transcriptomes reveals alternative exons whose expression is associated with metastasis. Cancer Res. 2010;70:896–905.PubMed
21.
Li C, Cai S, Wang X, Jiang Z. Identification and characterization of ANO9 in stage II and III colorectal carcinoma. Oncotarget. 2015;6:29324–34.PubMedPubMedCentral
22.
Jun I, Park HS, Piao H, et al. ANO9/TMEM16J promotes tumourigenesis via EGFR and is a novel therapeutic target for pancreatic cancer. Br J Cancer. 2017;117:1798–809.PubMedPubMedCentral
23.
Shiozaki A, Nako Y, Ichikawa D, et al. Role of the Na(+)/K(+)/2Cl(−) cotransporter NKCC1 in cell cycle progression in human esophageal squamous cell carcinoma. World J Gastroenterol. 2014;20:6844–59.PubMedPubMedCentral
24.
Shiozaki A, Takemoto K, Ichikawa D, et al. The K-Cl cotransporter KCC3 as an independent prognostic factor in human esophageal squamous cell carcinoma. Biomed Res Int. 2014;2014:936401.PubMedPubMedCentral
25.
Shiozaki A, Kudou M, Ichikawa D, et al. Expression and role of anion exchanger 1 in esophageal squamous cell carcinoma. Oncotarget. 2017;8:17921–35.PubMedPubMedCentral
26.
Shiozaki A, Hikami S, Ichikawa D, et al. Anion exchanger 2 suppresses cellular movement and has prognostic significance in esophageal squamous cell carcinoma. Oncotarget. 2018;9:25993–6006.PubMedPubMedCentral
27.
Shimizu H, Shiozaki A, Ichikawa D, et al. The expression and role of Aquaporin 5 in esophageal squamous cell carcinoma. J Gastroenterol. 2014;49:655–66.PubMed
28.
Miyazaki H, Shiozaki A, Niisato N, Marunaka Y. Physiological significance of hypotonicity-induced regulatory volume decrease: reduction in intracellular Cl– concentration acting as an intracellular signaling. Am J Physiol Renal Physiol. 2007;292:F1411–7.PubMed
29.
James DB, Mary KG, Christian W. International Union Against Cancer (UICC) TNM Classification of Malignant Tumors. 8th ed. Wiley, New York. 2017.
30.
Kuo YW, Trottier O, Mahamdeh M, Howard J. Spastin is a dual-function enzyme that severs microtubules and promotes their regrowth to increase the number and mass of microtubules. Proc Natl Acad Sci USA. 2019;116:5533–41.PubMedPubMedCentral
31.
Kumari A, Panda D. Regulation of microtubule stability by centrosomal proteins. IUBMB Life. 2018;70:602–11.PubMed
32.
Kumar A, Rajendran V, Sethumadhavan R, Purohit R. CEP proteins: the knights of centrosome dynasty. Protoplasma. 2013;250:965–83.PubMed
33.
Rock JR, Harfe BD. Expression of TMEM16 paralogs during murine embryogenesis. Dev Dyn. 2008;237:2566–74.PubMed
34.
Katoh M, Katoh M. Identification and characterization of human TP53I5 and mouse Tp53i5 genes in silico. Int J Oncol. 2004;25:225–30.PubMed
35.
Liu Z, Zhang S, Hou F, Zhang C, Gao J, Wang K. Inhibition of Ca(2+)-activated chloride channel ANO1 suppresses ovarian cancer through inactivating PI3K/Akt signaling. Int J Cancer. 2019;144:2215–26.PubMed
36.
Song Y, Gao J, Guan L, Chen X, Gao J, Wang K. Inhibition of ANO1/TMEM16A induces apoptosis in human prostate carcinoma cells by activating TNF-alpha signaling. Cell Death Dis. 2018;9:703.PubMedPubMedCentral
37.
Betleja E, Nanjundappa R, Cheng T, Mahjoub MR. A novel Cep120-dependent mechanism inhibits centriole maturation in quiescent cells. Elife. 2018;7:e35439.PubMedPubMedCentral
38.
Srsen V, Gnadt N, Dammermann A, Merdes A. Inhibition of centrosome protein assembly leads to p53-dependent exit from the cell cycle. J Cell Biol. 2006;174:625–30.PubMedPubMedCentral
39.
Gromley A, Jurczyk A, Sillibourne J, et al. A novel human protein of the maternal centriole is required for the final stages of cytokinesis and entry into S phase. J Cell Biol. 2003;161:535–45.PubMedPubMedCentral
40.
O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune response in tuberculosis. Annu Rev Immunol. 2013;31:475–527.PubMed
41.
42.
Kunzelmann K, Ousingsawat J, Benedetto R, Cabrita I, Schreiber R. Contribution of anoctamins to cell survival and cell death. Cancers (Basel). 2019;11(3):382.PubMedCentral
43.
Wanitchakool P, Ousingsawat J, Sirianant L, MacAulay N, Schreiber R, Kunzelmann K. Cl(−) channels in apoptosis. Eur Biophys J. 2016;45:599–610.PubMed
Metadata
Title
ANO9 Regulated Cell Cycle in Human Esophageal Squamous Cell Carcinoma
Authors
Keita Katsurahara, MD
Atsushi Shiozaki, MD, PhD
Toshiyuki Kosuga, MD, PhD
Michihiro Kudou, MD, PhD
Katsutoshi Shoda, MD, PhD
Tomohiro Arita, MD, PhD
Hirotaka Konishi, MD, PhD
Shuhei Komatsu, MD, PhD
Takeshi Kubota, MD, PhD
Hitoshi Fujiwara, MD, PhD
Kazuma Okamoto, MD, PhD
Mitsuo Kishimoto, MD, PhD
Eiichi Konishi
Yoshinori Marunaka, MD, PhD
Eigo Otsuji, MD, PhD
Publication date
01-09-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 9/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08368-y

Other articles of this Issue 9/2020

Annals of Surgical Oncology 9/2020 Go to the issue

Health Services Research and Global Oncology

Impact of Insurance Status on Survival in Gastroenteropancreatic Neuroendocrine Tumors

ASO Author Reflections

ASO Author Reflections: Effect Sizes of Whole Breast Radiotherapy and Systemic Therapies on Regional Recurrence Incidence in Breast Cancer Patients

Melanoma

The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma

ASO Author Reflections

ASO Author Reflections: Appropriate Candidates for Salvage Esophagectomy of Initially Unresectable Locally Advanced T4 Esophageal Squamous Cell Carcinoma

ASO Author Reflections

ASO Author Reflections: Hepatopancreatoduodenectomy: Why, When, and How?

ASO Author Reflections

ASO Author Reflections: Which is More Suitable for Surrogate Indicator of Gastric Cancer Patients’ Long-Term Prognosis: Lymph Nodes Examined Number or Lymph Node Noncompliance Rate?